[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shumin Yang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100615926",false,"NCT07298954","Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE)","Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism: A Multicenter, Randomized Trial","Inclusion Criteria:\n\n* Fully understand the study process, voluntarily agree to participate, and sign informed consent.\n* Diagnosed with primary aldosteronism. # Age 18-70 years with hypertension, any sex.\n\nExclusion Criteria:\n\n* Patients for whom AVS can be bypassed: Typical BPA (normal serum potassium and plasma aldosterone concentration (PAC) \\\u003C 110 pg\u002FmL, eligible for direct medical therapy); Typical UPA (PAC ≥ 200 pg\u002FmL, plasma renin concentration (PRC) ≤ 5 μIU\u002FmL, spontaneous hypokalemia, unilateral adrenal adenoma ≥ 1 cm with normal contralateral adrenal on CT or 68Ga-Pentixafor PET-CT indicating unilateral functional tumor, eligible for direct surgery);\n* Refusal of AVS or surgery, or contraindication to surgery.\n* Allergy to ACTH or contrast agents.\n* Combined with autonomous cortisol secretion (1 mg overnight dexamethasone suppression test cortisol ≥ 50 nmol\u002FL).\n* Early-onset hypertension (\\\u003C20 years) with hypokalemia and family history, suggestive of familial hyperaldosteronism or Liddle syndrome.\n* Imaging cannot exclude pheochromocytoma or adrenocortical carcinoma (nodule ≥ 4 cm, CT ≥ 20 HU, or MRI suggestive).\n* Active malignancy.\n* Previous adrenal surgery.\n* Chronic glucocorticoid use that cannot be discontinued.\n* Adrenal insufficiency requiring hormone replacement.\n* Pregnancy or breastfeeding; history of alcohol or substance abuse, or inability to cooperate due to psychiatric disorders.\n* NYHA class III-IV heart failure or hospitalization for worsening heart failure in the past 3 months, stroke or acute coronary syndrome in past 3 months, severe anemia (Hb \\\u003C 60 g\u002FL), severe liver or renal disease (ALT ≥ 3×upper limit; eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 or dialysis), systemic inflammatory response syndrome (SIRS), poorly controlled diabetes (FBG ≥ 13.3 mmol\u002FL), severe obesity (BMI ≥ 35 kg\u002Fm2), untreated aneurysm, or other conditions severely interfering with study participation.","ALL","18 Years","70 Years",{"count":19,"type":20},456,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a prospective, multicenter, randomized clinical trial aimed to compare the impact of three AVS diagnostic strategies on the clinical outcomes of patients with primary aldosteronism. The strategies include sequential combined AVS (non-ACTH-stimulated followed by ACTH-stimulated AVS), non- ACTH-stimulated AVS alone, and ACTH-stimulated AVS alone. The findings of this study will provide critical evidence for the clinical practice standards of AVS.",[26],"Primary Aldosteronism",[26,28,29,30,31,32],"Adrenal venous sampling","sequential combined AVS","non-ACTH-stimulated","ACTH-stimulated AVS","complete biochemical remission rate","RECRUITING","2025-12-22",{"date":36,"type":37},"2025-12-24","ACTUAL",{"date":39,"type":20},"2025-12-25",{"date":41,"type":20},"2028-12-31",{"name":43,"class":44},"Shumin Yang","OTHER",""]